Cognitive and metabolic outcomes of vildagliptin addition to the therapy in patients with type 2 diabetes mellitus: 26 week follow-up study

Bulut E. A., Alak Z. Y. S., Dokuzlar O., Kocyigit S. E., SOYSAL P., Smith L., ...More

ARCHIVES OF GERONTOLOGY AND GERIATRICS, vol.88, 2020 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 88
  • Publication Date: 2020
  • Doi Number: 10.1016/j.archger.2020.104013
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, ASSIA, Abstracts in Social Gerontology, BIOSIS, CAB Abstracts, CINAHL, EMBASE, MEDLINE, Psycinfo, Veterinary Science Database
  • Keywords: DPP-4 inhibitors, Cognitive decline, Metabolic outcome, Diabetes mellitus, Alzheimer's disease, Older adults, BRAIN MITOCHONDRIAL-FUNCTION, INSULIN-RESISTANCE, ALZHEIMERS-DISEASE, OXIDATIVE STRESS, RISK, SITAGLIPTIN, IMPAIRMENT, INHIBITORS, DEMENTIA, MEMORY
  • Dokuz Eylül University Affiliated: Yes


Aims: Type 2 Diabetes Mellitus(DM) is a well-known risk factor for cognitive impairment. Recent evidences suggest that Dipeptidyl peptidase-4(DPP-4) inhibitors might have neuroprotective effects. Therefore, this study aimed to investigate vildagliptin, a DPP-4 inhibitor, effects on cognitive function in older patients with DM.